A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms (NCT00441896) | Clinical Trial Compass
CompletedPhase 2
A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms
United States57 participantsStarted 2007-01
Plain-language summary
The study consists of cohorts where participants are randomized, in a 2:1 ratio, to 1 of 2 sequences, A and B. In each cohort, Sequence A, comprised of participants, who will receive ascending doses of ganaxolone and ascending doses of placebo. Sequence B, comprised of participants, who will receive ascending doses of placebo and ascending doses of ganaxolone. The dosing level in each subsequent cohort will be based upon experience gained from previous cohorts.
Who can participate
Age range4 Months – 24 Months
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Be diagnosed with IS (regardless of etiology- except for a progressive neurologic illness). Diagnostic Criteria: Seizures consisting of single or repetitive short muscular contractions leading to flexion or extension. Spasms may be characterized as tonic or myoclonic contractions, may occur singly or in clusters, and typically occur bilaterally and symmetrically. The EEG pattern must be consistent with the diagnosis of IS (hypsarrhythmia, modified hypsarrhythmia, multifocal spike wave discharges, etc).
* Have a vEEG recording confirming the diagnosis of IS.
* Have had a magnetic resonance imaging (MRI) performed to determine any possible causes of IS.
* Have been previously treated with 3 or fewer AEDs.
* If being treated with concomitant AEDs
* Current AEDs have been at a constant daily dose for at least 2 weeks; Note: Subjects with minor dose adjustments may be allowed to enter the study after shorter periods after detailed discussion with the medical monitor.
* Have a stable clinical response/plateau for at least 2 weeks
* Are able to continue treatment with no more than 2 concomitant AEDs (ACTH, corticosteroids, felbamate, and vigabatrin are not allowed concomitantly).
* A ketogenic diet is permitted if it can be maintained for the duration of the study.
* Be a male or female, 4 to 24 months of age (inclusive)
* Have a Parent/Guardian who is properly informed of the nature and risks of the clinical study, who is willing and capable of compl…
What they're measuring
1
Change From Baseline in Frequency of Spasm Clusters at Day 10